CV Pharm Course Clinical Correlate Articles http://www.imhotepvirtualmedsch.com/ans--and-cv-pharm-course.php

1. Cardiogenic Shock in Emergency Medicine http://emedicine.medscape.com/article/759992-overview
Author: Ethan S Brandler, MD, MPH; Chief Editor: David FM Brown, MD more...
Updated: Nov 2, 2010
Background
Cardiogenic shock is characterized by a decreased pumping ability of the heart that causes a shocklike state (ie,
global hypoperfusion). It most commonly occurs in association with, and as a direct result of, acute myocardial
infarction (AMI).
Similar to other shock states, cardiogenic shock is considered to be a clinical diagnosis characterized by decreased
urine output, altered mentation, and hypotension. Other clinical characteristics include jugular venous distension,
cardiac gallop, and pulmonary edema. The most recent prospective study of cardiogenic shock defines cardiogenic
shock as sustained hypotension (systolic blood pressure [BP] less than 90 mm Hg lasting more than 30 min) with
evidence of tissue hypoperfusion with adequate left ventricular (LV) filling pressure.[1] Tissue hypoperfusion was
defined as cold peripheries (extremities colder than core), oliguria (< 30 mL/h), or both.
For related information, see Medscape's Cardiology Resource Centers.
Pathophysiology
The most common initiating event in cardiogenic shock is AMI. Dead myocardium does not contract, and classical
teaching has been that when more than 40% of the myocardium is irreversibly damaged (particularly, the anterior
cardiac wall), cardiogenic shock may result. On a mechanical level, a marked decrease in contractility reduces the
ejection fraction and cardiac output. These lead to increased ventricular filling pressures, cardiac chamber dilatation,
and ultimately univentricular or biventricular failure that result in systemic hypotension and/or pulmonary edema. The
SHOCK trial, however, demonstrated that left ventricular ejection fraction is not always depressed in the setting of
cardiogenic shock. Additional surprising findings included nonelevated systemic vascular resistance on vasopressors
and that most survivors have only New York Heart Association (NYHA) class I congestive heart failure.
A systemic inflammatory response syndrome–type mechanism has been implicated in the pathophysiology of
cardiogenic shock. Elevated levels of white blood cells, body temperature, complement, interleukins, and C-reactive
protein are often seen in large myocardial infarctions. Similarly, inflammatory nitric oxide synthetase (iNOS) is also
released in high levels during myocardial stress. iNOS induces nitric oxide production, which may uncouple calcium
metabolism in the myocardium resulting in a stunned myocardium. Additionally, iNOS leads to the expression of
interleukins, which may themselves cause hypotension.
Myocardial ischemia causes a decrease in contractile function, which leads to left ventricular dysfunction and
decreased arterial pressure; these, in turn, exacerbate the myocardial ischemia. The end result is a vicious cycle that
leads to severe cardiovascular decompensation. Other pathophysiological mechanisms responsible for cardiogenic
shock include papillary muscle rupture leading to acute mitral regurgitation (4.4%); decreased forward flow, ejection
fraction, and ventricular septal defect (1.5%); and free wall rupture (4.1%) as a consequence of AMI.
Right ventricular (RV) infarct, by itself, may lead to hypotension and shock because of reduced preload to the left
ventricle. The management of RV infarcts is discussed elsewhere but should be considered in the setting of inferior
wall MI.
Cardiac tamponade may result as a consequence of pericarditis, uremic pericardial effusion, or in rare cases systemic
lupus erythematosus.
Whenever patients who present in shock have been exposed to medications that may cause hypotension, these drugs
should be considered as possible culprits in the disease. Calcium channel blockers may cause profound hypotension
with a normal or elevated heart rate. Beta-blocking agents may also cause hypotension. Hypotension can be seen with
or without bradycardia, or AV node block can be seen with either of these types of medications. If these medications
1 of 8 9/3/2011 8:28 AM

2. Cardiogenic Shock in Emergency Medicine http://emedicine.medscape.com/article/759992-overview
are the culprits, therapy directed at these toxicities is beneficial. Nitroglycerin, angiotensin-converting enzyme
inhibitors, opiate, and barbiturates can all cause a shock state and may be difficult to distinguish from cardiogenic
shock.
Initiating events other than AMI and ischemia include infection, drug toxicity, and pulmonary embolus.
For children, the causes of cardiogenic shock are vastly different. The 3 primary causes of cardiogenic shock in
children and infants are viral myocarditis, congenital heart disease, and toxic ingestions. For details, see eMedicine's
Pediatric Critical Care Medicine article on Shock.
Epidemiology
Frequency
United States
Cardiogenic shock occurs in 8.6% of patients with ST-segment elevation MI with 29% of those presenting to the
hospital already in shock. It occurs only in 2% of patients with non–ST-segment elevation MI.
Mortality/Morbidity
Cardiogenic shock is the leading cause of death in acute myocardial infarction (AMI).
The overall in-hospital mortality rate is 57%. For persons older than 75 years, the mortality rate is 64.1%. For
those younger than 75 years, the mortality rate is 39.5%.
Outcomes significantly improve only when rapid revascularization can be achieved. The SHOCK trial
demonstrated that overall mortality when revascularization occurs is 38%. When rapid revascularization is not
attempted, mortality rates approach 70%.
Rates vary depending on the procedure (eg, percutaneous transluminal coronary angioplasty, stent placement,
thrombolytic therapy), but they have been reported to be as low as 30-50%.
Mortality rates have declined over time. In the National Registry of Myocardial Infarction covering the period
from 1995-2004, in-hospital mortality declined from 60.3% to 47.9%.[2] This improvement has been attributed
to the increasing frequency of the use percutaneous coronary intervention (PCI) and other revascularization
procedures. Mortality rates attributable to cardiogenic shock are also thought to be due to the increased
frequency of use of PCI, antiplatelet therapies, and lipid-lowering agents in patients with acute coronary
syndromes. This has decreased the incidence of cardiogenic shock developing in the hospital due to acute
coronary syndromes. The incidence of cardiogenic shock on arrival to the hospital has not changed
significantly.[3, 4]
Race
Race-stratified mortality rates are as follows: Hispanics, 74%; African Americans, 65%; whites, 56%; and
Asians/others, 41%.
Race-based differences in mortality disappear with revascularization.
Sex
Women comprise 42% of all patients with cardiogenic shock.
Age
Median age for cardiogenic shock mirrors the bimodal distribution of disease. For adults, the median age ranges from
65-66 years. For children, cardiogenic shock presents as a consequence of fulminant myocarditis or congenital heart
disease.
Contributor Information and Disclosures
Author
Ethan S Brandler, MD, MPH Clinical Assistant Professor, Attending Physician, Departments of Emergency
Medicine and Internal Medicine, University Hospital of Brooklyn, Kings County Hospital
2 of 8 9/3/2011 8:28 AM

3. Cardiogenic Shock in Emergency Medicine http://emedicine.medscape.com/article/759992-overview
Ethan S Brandler, MD, MPH is a member of the following medical societies: American College of Emergency
Physicians and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.
Coauthor(s)
Richard H Sinert, DO Associate Professor of Emergency Medicine, Clinical Assistant Professor of Medicine,
Research Director, State University of New York College of Medicine; Consulting Staff, Department of Emergency
Medicine, Kings County Hospital Center
Richard H Sinert, DO is a member of the following medical societies: American College of Physicians and Society
for Academic Emergency Medicine
Disclosure: Nothing to disclose.
Specialty Editor Board
Daniel J Dire, MD, FACEP, FAAP, FAAEM Clinical Professor, Department of Emergency Medicine, University of
Texas-Houston; Clinical Professor, Department of Pediatrics, University of Texas Health Sciences Center, San
Antonio, Texas
Daniel J Dire, MD, FACEP, FAAP, FAAEM is a member of the following medical societies: American Academy of
Clinical Toxicology, American Academy of Emergency Medicine, American Academy of Pediatrics, American
College of Emergency Physicians, and Association of Military Surgeons of the US
Disclosure: Talecris Biotherapeutics Honoraria Speaking and teaching
Francisco Talavera, PharmD, PhD Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment
A Antoine Kazzi, MD Chair and Medical Director, Department of Emergency Medicine, American University of
Beirut, Lebanon
A Antoine Kazzi, MD is a member of the following medical societies: American Academy of Emergency Medicine
Disclosure: Nothing to disclose.
John D Halamka, MD, MS Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess
Medical Center; Chief Information Officer, CareGroup Healthcare System and Harvard Medical School; Attending
Physician, Division of Emergency Medicine, Beth Israel Deaconess Medical Center
John D Halamka, MD, MS is a member of the following medical societies: American College of Emergency
Physicians, American Medical Informatics Association, Phi Beta Kappa, and Society for Academic Emergency
Medicine
Disclosure: Nothing to disclose.
Chief Editor
David FM Brown, MD Associate Professor, Division of Emergency Medicine, Harvard Medical School; Vice
Chair, Department of Emergency Medicine, Massachusetts General Hospital
David FM Brown, MD is a member of the following medical societies: American College of Emergency Physicians
and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.
References
1. Hochman JS, Sleeper LA, Webb JG, Sanborn TA, White HD, Talley JD, et al. Early revascularization in acute
myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently
Revascularize Occluded Coronaries for Cardiogenic Shock. N Engl J Med. Aug 26 1999;341(9):625-34.
[Medline].
3 of 8 9/3/2011 8:28 AM

4. Cardiogenic Shock in Emergency Medicine http://emedicine.medscape.com/article/759992-overview
2. Babaev A, Frederick PD, Pasta DJ, Every N, Sichrovsky T, Hochman JS. Trends in management and
outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. JAMA. Jul 27
2005;294(4):448-54. [Medline].
3. Fox KA, Steg PG, Eagle KA, Goodman SG, Anderson FA Jr, Granger CB. Decline in rates of death and heart
failure in acute coronary syndromes, 1999-2006. JAMA. May 2 2007;297(17):1892-900. [Medline].
4. Jeger RV, Radovanovic D, Hunziker PR, Pfisterer ME, Stauffer JC, Erne P, et al. Ten-year trends in the
incidence and treatment of cardiogenic shock. Ann Intern Med. Nov 4 2008;149(9):618-26. [Medline].
5. Reynolds HR, Hochman JS. Cardiogenic shock: current concepts and improving outcomes. Circulation. Feb
5 2008;117(5):686-97. [Medline].
6. Al-Reesi A, Al-Zadjali N, Perry J, Fergusson D, Al-Shamsi M, Al-Thagafi M, et al. Do beta-blockers reduce
short-term mortality following acute myocardial infarction? A systematic review and meta-analysis. CJEM. May
2008;10(3):215-23. [Medline].
7. Chen ZM, Pan HC, Chen YP, Peto R, Collins R, Jiang LX. Early intravenous then oral metoprolol in 45,852
patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. Nov 5
2005;366(9497):1622-32. [Medline].
8. Hamon M, Agostini D, Le Page O, Riddell JW, Hamon M. Prognostic impact of right ventricular involvement in
patients with acute myocardial infarction: meta-analysis. Crit Care Med. Jul 2008;36(7):2023-33. [Medline].
9. Jeger RV, Lowe AM, Buller CE, Pfisterer ME, Dzavik V, Webb JG, et al. Hemodynamic parameters are
prognostically important in cardiogenic shock but similar following early revascularization or initial medical
stabilization: a report from the SHOCK Trial. Chest. Dec 2007;132(6):1794-803. [Medline].
10. Hochman JS, Sleeper LA, White HD. One-year survival following early revascularization for cardiogenic
shock. JAMA. Jan 10 2001;285(2):190-2. [Medline].
11. Ellender TJ, Skinner JC. The use of vasopressors and inotropes in the emergency medical treatment of
shock. Emerg Med Clin North Am. Aug 2008;26(3):759-86, ix. [Medline].
12. Naples RM, Harris JW, Ghaemmaghami CA. Critical care aspects in the management of patients with acute
coronary syndromes. Emerg Med Clin North Am. Aug 2008;26(3):685-702, viii. [Medline].
13. Fuhrmann JT, Schmeisser A, Schulze MR, Wunderlich C, Schoen SP, Rauwolf T. Levosimendan is superior
to enoximone in refractory cardiogenic shock complicating acute myocardial infarction. Crit Care Med. Aug
2008;36(8):2257-66. [Medline].
14. De Luca L, Colucci WS, Nieminen MS, Massie BM, Gheorghiade M. Evidence-based use of levosimendan in
different clinical settings. Eur Heart J. Aug 2006;27(16):1908-20. [Medline].
15. Garatti A, Russo C, Lanfranconi M, Colombo T, Bruschi G, Trunfio S, et al. Mechanical circulatory support for
cardiogenic shock complicating acute myocardial infarction: an experimental and clinical review. ASAIO J.
May-Jun 2007;53(3):278-87. [Medline].
16. Cheng JM, den Uil CA, Hoeks SE, van der Ent M, Jewbali LS, van Domburg RT, et al. Percutaneous left
ventricular assist devices vs. intra-aortic balloon pump counterpulsation for treatment of cardiogenic shock: a
meta-analysis of controlled trials. Eur Heart J. Sep 2009;30(17):2102-8. [Medline].
17. Windecker S. Percutaneous left ventricular assist devices for treatment of patients with cardiogenic shock.
Curr Opin Crit Care. Oct 2007;13(5):521-7. [Medline].
18. Amin AP, Nathan S, Prodduturi P, D'Silva O, Gupta A, Kumar A. Survival benefit from early revascularization in
elderly patients with cardiogenic shock after acute myocardial infarction: a cohort study. J Invasive Cardiol.
Jul 2009;21(7):305-12. [Medline].
19. Ander DS, Jaggi M, Rivers E, Rady MY, Levine TB, Levine AB, et al. Undetected cardiogenic shock in
patients with congestive heart failure presenting to the emergency department. Am J Cardiol. Oct 1
1998;82(7):888-91. [Medline].
20. Antoniucci D, Valenti R, Santoro GM, Bolognese L, Trapani M, Moschi G, et al. Systematic direct angioplasty
and stent-supported direct angioplasty therapy for cardiogenic shock complicating acute myocardial
4 of 8 9/3/2011 8:28 AM

5. Cardiogenic Shock in Emergency Medicine http://emedicine.medscape.com/article/759992-overview
infarction: in-hospital and long-term survival. J Am Coll Cardiol. Feb 1998;31(2):294-300. [Medline].
21. Archan S, Toller W. Levosimendan: current status and future prospects. Curr Opin Anaesthesiol. Feb
2008;21(1):78-84. [Medline].
22. Barry WL, Sarembock IJ. Cardiogenic shock: therapy and prevention. Clinical Cardiology. 1998;21:72-80.
[Medline].
23. Bellone A, Monari A, Cortellaro F, Vettorello M, Arlati S, Coen D. Myocardial infarction rate in acute pulmonary
edema: noninvasive pressure support ventilation versus continuous positive airway pressure. Crit Care Med.
Sep 2004;32(9):1860-5. [Medline].
24. Bengtson JR, Kaplan AJ, Pieper KS, Wildermann NM, Mark DB, Pryor DB, et al. Prognosis in cardiogenic
shock after acute myocardial infarction in the interventional era. J Am Coll Cardiol. Dec 1992;20(7):1482-9.
[Medline].
25. Brodie BR, Stuckey TD, Hansen C, Muncy D. Intra-aortic balloon counterpulsation before primary
percutaneous transluminal coronary angioplasty reduces catheterization laboratory events in high-risk patients
with acute myocardial infarction. Am J Cardiol. Jul 1 1999;84(1):18-23. [Medline].
26. Bur A, Bayegan K, Holzer M, Herkner H, Schreiber W, Siostrzonek P, et al. Intra-aortic balloon
counterpulsation in the emergency department: a 7-year review and analysis of predictors of survival.
Resuscitation. Jun 2002;53(3):259-64. [Medline].
27. Burger AJ, Elkayam U, Neibaur MT. Comparison of the occurrence of ventricular arrhythmias in patients with
acutely decompensated congestive heart failure receiving dobutamine versus nesiritide therapy. Am J
Cardiol. Jul 1 2001;88(1):35-9. [Medline].
28. Ciccone TJ, Grossman SA. Cardiac ultrasound. Emerg Med Clin North Am. Aug 2004;22(3):621-40.
[Medline].
29. den Uil CA, Lagrand WK, Valk SD, Spronk PE, Simoons ML. Management of cardiogenic shock: focus on
tissue perfusion. Curr Probl Cardiol. Aug 2009;34(8):330-49. [Medline].
30. Doust JA, Pietrzak E, Dobson A, Glasziou P. How well does B-type natriuretic peptide predict death and
cardiac events in patients with heart failure: systematic review. BMJ. Mar 19 2005;330(7492):625. [Medline].
31. Dzavik V, Sleeper LA, Cocke TP, Moscucci M, Saucedo J, Hosat S, et al. Early revascularization is associated
with improved survival in elderly patients with acute myocardial infarction complicated by cardiogenic shock: a
report from the SHOCK Trial Registry. Eur Heart J. May 2003;24(9):828-37. [Medline].
32. Dzavík V, Burton JR, Kee C, Teo KK, Ignaszewski A, Lucas AR, et al. Changing practice patterns in the
management of acute myocardial infarction complicated by cardiogenic shock: elderly compared with
younger patients. Can J Cardiol. Jul 1998;14(7):923-30. [Medline].
33. Fuhrmann JT, Schmeisser A, Schulze MR, Wunderlich C, Schoen SP, Rauwolf T, et al. Levosimendan is
superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction. Crit Care
Med. Aug 2008;36(8):2257-66. [Medline].
34. Goldberg RJ, Samad NA, Yarzebski J, Gurwitz J, Bigelow C, Gore JM. Temporal trends in cardiogenic shock
complicating acute myocardial infarction. N Engl J Med. Apr 15 1999;340(15):1162-8. [Medline].
35. Gowda RM, Fox JT, Khan IA. Cardiogenic shock: basics and clinical considerations. Int J Cardiol. Jan 24
2008;123(3):221-8. [Medline].
36. Gurm HS, Bates ER. Cardiogenic shock complicating myocardial infarction. Crit Care Clin. Oct
2007;23(4):759-77, vi. [Medline].
37. Hasdai D, Califf RM, Thompson TD, Hochman JS, Ohman EM, Pfisterer M, et al. Predictors of cardiogenic
shock after thrombolytic therapy for acute myocardial infarction. J Am Coll Cardiol. Jan 2000;35(1):136-43.
[Medline].
38. Hasdai D, Holmes DR Jr, Califf RM, Thompson TD, Hochman JS, Pfisterer M, et al. Cardiogenic shock
complicating acute myocardial infarction: predictors of death. GUSTO Investigators. Global Utilization of
Streptokinase and Tissue-Plasminogen Activator for Occluded Coronary Arteries. Am Heart J. Jul
5 of 8 9/3/2011 8:28 AM

6. Cardiogenic Shock in Emergency Medicine http://emedicine.medscape.com/article/759992-overview
1999;138(1 Pt 1):21-31. [Medline].
39. Hochman JS, Buller CE, Sleeper LA, Boland J, Dzavik V, Sanborn TA, et al. Cardiogenic shock complicating
acute myocardial infarction--etiologies, management and outcome: a report from the SHOCK Trial Registry.
SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK?. J Am Coll Cardiol. Sep
2000;36(3 Suppl A):1063-70. [Medline].
40. Hollenberg SM, Kavinsky CJ, Parrillo JE. Cardiogenic shock. Ann Intern Med. Jul 6 1999;131(1):47-59.
[Medline].
41. Holmes CL, Walley KR. The evaluation and management of shock. Clin Chest Med. Dec 2003;24(4):775-89.
[Medline].
42. Holmes DR Jr, Califf RM, Van de Werf F, Berger PB, Bates ER, Simoons ML, et al. Difference in countries'
use of resources and clinical outcome for patients with cardiogenic shock after myocardial infarction: results
from the GUSTO trial. Lancet. Jan 11 1997;349(9045):75-8. [Medline].
43. Iakobishvili Z, Behar S, Boyko V, Battler A, Hasdai D. Does current treatment of cardiogenic shock
complicating the acute coronary syndromes comply with guidelines?. Am Heart J. Jan 2005;149(1):98-103.
[Medline].
44. Jacobs AK, French JK, Col J, Sleeper LA, Slater JN, Carnendran L, et al. Cardiogenic shock with non-ST-
segment elevation myocardial infarction: a report from the SHOCK Trial Registry. SHould we emergently
revascularize Occluded coronaries for Cardiogenic shocK?. J Am Coll Cardiol. Sep 2000;36(3 Suppl
A):1091-6. [Medline].
45. Jones AE, Craddock PA, Tayal VS, Kline JA. Diagnostic accuracy of left ventricular function for identifying
sepsis among emergency department patients with nontraumatic symptomatic undifferentiated hypotension.
Shock. Dec 2005;24(6):513-7. [Medline].
46. Katayama T, Nakashima H, Takagi C. Predictors of mortality in patients with acute myocardial infarction and
cardiogenic shock. Circ J. Jan 2005;69(1):83-8. [Medline].
47. Klocke RK, Mager G, Kux A, Hopp HW, Hilger HH. Effects of a twenty-four-hour milrinone infusion in patients
with severe heart failure and cardiogenic shock as a function of the hemodynamic initial condition. Am Heart
J. Jun 1991;121(6 Pt 2):1965-73. [Medline].
48. Kohsaka S, Menon V, Lowe AM. Systemic inflammatory response syndrome after acute myocardial infarction
complicated by cardiogenic shock. Arch Intern Med. Jul 25 2005;165(14):1643-50. [Medline].
49. Mark DG, Ku BS, Carr BG, Everett WW, Okusanya O, Horan A, et al. Directed bedside transthoracic
echocardiography: preferred cardiac window for left ventricular ejection fraction estimation in critically ill
patients. Am J Emerg Med. Oct 2007;25(8):894-900. [Medline].
50. Mendes LA, Picard MH, Sleeper LA, Thompson CR, Jacobs AK, White HD, et al. Cardiogenic shock:
predictors of outcome based on right and left ventricular size and function at presentation. Coron Artery Dis.
Jun 2005;16(4):209-15. [Medline].
51. Menon V, Hochman JS, Stebbins A. Lack of progress in cardiogenic shock: lessons from the GUSTO trials.
Eur Heart J. Dec 2000;21(23):1928-36. [Medline].
52. Mukae S, Yanagishita T, Geshi E, Umetsu K, Tomita M, Itoh S, et al. The effects of dopamine, dobutamine
and amrinone on mitochondrial function in cardiogenic shock. Jpn Heart J. Jul 1997;38(4):515-29. [Medline].
53. Palmeri ST, Lowe AM, Sleeper LA. Racial and ethnic differences in the treatment and outcome of cardiogenic
shock following acute myocardial infarction. Am J Cardiol. Oct 15 2005;96(8):1042-9. [Medline].
54. Perez-Castellano N, Garcia E, Serrano JA, Elizaga J, Soriano J, Abeytua M, et al. Efficacy of invasive strategy
for the management of acute myocardial infarction complicated by cardiogenic shock. Am J Cardiol. Apr 1
1999;83(7):989-93. [Medline].
55. Rackley CE, Russell RO Jr, Mantle JA, Rogers WJ. Cardiogenic shock. Cardiovasc Clin. 1981;11(3):15-24.
[Medline].
56. Randazzo MR, Snoey ER, Levitt MA, Binder K. Accuracy of emergency physician assessment of left
6 of 8 9/3/2011 8:28 AM

7. Cardiogenic Shock in Emergency Medicine http://emedicine.medscape.com/article/759992-overview
ventricular ejection fraction and central venous pressure using echocardiography. Acad Emerg Med. Sep
2003;10(9):973-7. [Medline].
57. Russ MA, Prondzinsky R, Christoph A, Schlitt A, Buerke U, Soffker G, et al. Hemodynamic improvement
following levosimendan treatment in patients with acute myocardial infarction and cardiogenic shock. Crit
Care Med. Dec 2007;35(12):2732-9. [Medline].
58. [Guideline] Ryan TJ, Antman EM, Brooks NH, Califf RM, Hillis LD, Hiratzka LF, et al. 1999 update: ACC/AHA
Guidelines for the Management of Patients With Acute Myocardial Infarction: Executive Summary and
Recommendations: A report of the American College of Cardiology/American Heart Association Task Force
on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Circulation. Aug 31
1999;100(9):1016-30. [Medline].
59. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients
with acutely decompensated heart failure. Circulation. Mar 29 2005;111(12):1487-91. [Medline].
60. Sanborn TA, Sleeper LA, Bates ER. Impact of thrombolysis, intra-aortic balloon pump counterpulsation, and
their combination in cardiogenic shock complicating acute myocardial infarction: a report from the SHOCK
Trial Registry. SHould we emergently revascularize Occluded Coronaries for. J Am Coll Cardiol. Sep
2000;36(3 Suppl A):1123-9. [Medline].
61. Singh M, White J, Hasdai D, Hodgson PK, Berger PB, Topol EJ. Long-term outcome and its predictors
among patients with ST-segment elevation myocardial infarction complicated by shock: insights from the
GUSTO-I trial. J Am Coll Cardiol. Oct 30 2007;50(18):1752-8. [Medline].
62. [Best Evidence] Sleeper LA, Ramanathan K, Picard MH, Lejemtel TH, White HD, Dzavik V, et al. Functional
status and quality of life after emergency revascularization for cardiogenic shock complicating acute
myocardial infarction. J Am Coll Cardiol. Jul 19 2005;46(2):266-73. [Medline].
63. Smilth L, Hernan L. Shock States. In: Fuhrman BP, Zimmerman JJ, eds. Pediatric Critical Care. 3rd ed.
Philadelphia, PA: Mosby Inc; 2006:chap 27.
64. Stone PH, Raabe DS, Jaffe AS, et al. Prognostic significance of location and type of myocardial infarction:
independent adverse outcome associated with anterior location. J Am Coll Cardiol. Mar 1988;11(3):453-63.
[Medline].
65. Tan LB, Littler WA. Measurement of cardiac reserve in cardiogenic shock: implications for prognosis and
management. Br Heart J. Aug 1990;64(2):121-8. [Medline].
66. Topalian S, Ginsberg F, Parrillo JE. Cardiogenic shock. Crit Care Med. Jan 2008;36(1 Suppl):S66-74.
[Medline].
67. Topalian S, Ginsberg F, Parrillo JE. Cardiogenic shock. Crit Care Med. Jan 2008;36(1 Suppl):S66-74.
[Medline].
68. [Best Evidence] TRIUMPH Investigators, Alexander JH, Reynolds HR, Stebbins AL, Dzavik V, Harrington RA.
Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH
randomized controlled trial. JAMA. Apr 18 2007;297(15):1657-66. [Medline].
69. Tung RH, Garcia C, Morss AM. Utility of B-type natriuretic peptide for the evaluation of intensive careunit
shock. Crit Care Med. Aug 2004;32(8):1643-7. [Medline].
70. Urban P, Stauffer JC, Bleed D, Khatchatrian N, Amann W, Bertel O, et al. A randomized evaluation of early
revascularization to treat shock complicating acute myocardial infarction. The (Swiss) Multicenter Trial of
Angioplasty for Shock-(S)MASH. Eur Heart J. Jul 1999;20(14):1030-8. [Medline].
71. Valente S, Lazzeri C, Chiostri M, Sori A, Giglioli C, Salvadori C, et al. Time of onset and outcome of
cardiogenic shock in acute coronary syndromes. J Cardiovasc Med (Hagerstown). Dec 2008;9(12):1235-40.
[Medline].
72. [Best Evidence] Wang CS, FitzGerald JM, Schulzer M, Mak E, Ayas NT. Does this dyspneic patient in the
emergency department have congestive heart failure?. JAMA. Oct 19 2005;294(15):1944-56. [Medline].
73. Webb JG. Interventional management of cardiogenic shock. Can J Cardiol. Feb 1998;14(2):233-44.
[Medline].
7 of 8 9/3/2011 8:28 AM

8. Cardiogenic Shock in Emergency Medicine http://emedicine.medscape.com/article/759992-overview
74. Webb JG, Carere RG, Hilton JD, Rabinowitz A, Buller E, Dodek AA, et al. Usefulness of coronary stenting for
cardiogenic shock. Am J Cardiol. Jan 1 1997;79(1):81-4. [Medline].
75. Webb JG, Lowe AM, Sanborn TA, White HD, Sleeper LA, Carere RG, et al. Percutaneous coronary
intervention for cardiogenic shock in the SHOCK trial. J Am Coll Cardiol. Oct 15 2003;42(8):1380-6.
[Medline].
76. Webb JG, Sleeper LA, Buller CE. Implications of the timing of onset of cardiogenic shock after acute
myocardial infarction: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded
Coronaries for cardiogenic shocK?. J Am Coll Cardiol. Sep 2000;36(3 Suppl A):1084-90. [Medline].
77. White HD, Assmann SF, Sanborn TA, Jacobs AK, Webb JG, Sleeper LA, et al. Comparison of percutaneous
coronary intervention and coronary artery bypass grafting after acute myocardial infarction complicated by
cardiogenic shock: results from the Should We Emergently Revascularize Occluded Coronaries for
Cardiogenic Shock (SHOCK) trial. Circulation. Sep 27 2005;112(13):1992-2001. [Medline].
78. White HD, Palmeri ST, Sleeper LA, French JK, Wong CK, Lowe AM, et al. Electrocardiographic findings in
cardiogenic shock, risk prediction, and the effects of emergency revascularization: results from the SHOCK
trial. Am Heart J. Nov 2004;148(5):810-7. [Medline].
79. Wong SC, Sanborn T, Sleeper LA, Webb JG, Pilchik R, Hart D, et al. Angiographic findings and clinical
correlates in patients with cardiogenic shock complicating acute myocardial infarction: a report from the
SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK?. J
Am Coll Cardiol. Sep 2000;36(3 Suppl A):1077-83. [Medline].
80. Wong SC, Sleeper LA, Monrad ES, Menegus MA, Palazzo A, Dzavik V, et al. Absence of gender differences
in clinical outcomes in patients with cardiogenic shock complicating acute myocardial infarction. A report from
the SHOCK Trial Registry. J Am Coll Cardiol. Nov 1 2001;38(5):1395-401. [Medline].
8 of 8 9/3/2011 8:28 AM